Neurocognitive Disorders

Leqembi Iqlik Now Available for Maintenance Dosing in Early Alzheimer Disease

Diana Ernst, RPh
|
Publish Date
To help support patients with at-home administration, Eisai and Biogen have launched the Leqembi Companion program.

Leqembi® Iqlik™, a subcutaneous (SC) formulation of lecanemab, is now available as a maintenance dosing regimen for the treatment of Alzheimer disease in patients with mild cognitive impairment or mild dementia stage of disease.

Lecanemab-irmb is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. Previously, it was only available for administration as an intravenous (IV) infusion.

The SC formulation is supplied as a 360mg/1.8mL single-dose prefilled autoinjector and is intended for maintenance dosing only. Following 18 months of IV lecanemab (10mg/kg every 2 weeks), patients may now transition to an SC maintenance dosage of 360mg once weekly using the Leqembi Iqlik autoinjector or continue with the IV infusions every 4 weeks. 

Leqembi Iqlik may be administered by a patient or caregiver after proper training in SC injection technique. To help support patients, Eisai and Biogen have launched the Leqembi Companion™ program, which offers injection education and other medication management tools to prepare patients for at-home treatment administration.

This article originally appeared on MPR

References:
  1. Eisai and Biogen announce US availability of Leqembi® Iqlik™ (lecanemab-irmb) subcutaneous injection maintenance dose for treatment of early Alzheimer’s disease. News release. Eisai and Biogen. October 6, 2025. https://www.prnewswire.com/news-releases/eisai-and-biogen-announce-us-availability-of-leqembi-iqlik-lecanemab-irmb-subcutaneous-injection-maintenance-dose-for-treatment-of-early-alzheimers-disease-302576192.html.
  2. Leqembi. Package insert. Eisai and Biogen; 2025. Accessed October 7, 2025. https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf?hash=a88be7f8-601d-4c21-847d-790c0186ef18.